Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Orphan Nuclear Receptor RORα Regulates Enzymatic Metabolism of Cerebral 24S-Hydroxycholesterol through CYP39A1 Intronic Response Element Activation.

Tytuł:
Orphan Nuclear Receptor RORα Regulates Enzymatic Metabolism of Cerebral 24S-Hydroxycholesterol through CYP39A1 Intronic Response Element Activation.
Autorzy:
Matsuoka H; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Katayama M; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Ohishi A; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Miya K; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Tokunaga R; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Kobayashi S; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Nishimoto Y; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Hirooka K; Department of Biotechnology, Faculty of Life Science and Biotechnology, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Shima A; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Michihara A; Laboratory of Genome Function and Pathophysiology, Faculty of Pharmacy and Pharmaceutical Sciences, Fukuyama University, Fukuyama, Hiroshima 729-0292, Japan.
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2020 May 07; Vol. 21 (9). Date of Electronic Publication: 2020 May 07.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: Basel, Switzerland : MDPI, [2000-
MeSH Terms:
Brain/*metabolism
Hydroxycholesterols/*metabolism
Nuclear Receptor Subfamily 1, Group F, Member 1/*metabolism
Steroid Hydroxylases/*genetics
Gene Expression Regulation ; HEK293 Cells ; Hep G2 Cells ; Humans ; Hydroxycholesterols/blood ; Introns ; Nuclear Receptor Subfamily 1, Group F, Member 1/genetics ; Response Elements ; Steroid Hydroxylases/chemistry ; Steroid Hydroxylases/metabolism
References:
Nature. 1996 Feb 22;379(6567):736-9. (PMID: 8602221)
Exp Gerontol. 2015 Aug;68:13-8. (PMID: 25261765)
J Lipid Res. 1998 Aug;39(8):1594-600. (PMID: 9717719)
Science. 2002 Jul 19;297(5580):353-6. (PMID: 12130773)
Nat Rev Drug Discov. 2014 Mar;13(3):197-216. (PMID: 24577401)
Biochimie. 2013 Mar;95(3):595-612. (PMID: 23041502)
J Alzheimers Dis. 2015;44(3):827-38. (PMID: 25362032)
Mol Pharmacol. 2008 Mar;73(3):891-9. (PMID: 18055760)
BMC Mol Cell Biol. 2020 Apr 22;21(1):32. (PMID: 32321446)
Physiol Genomics. 2007 Oct 22;31(2):281-94. (PMID: 17666523)
Exp Biol Med (Maywood). 2008 Oct;233(10):1191-201. (PMID: 18535165)
Prog Lipid Res. 2016 Oct;64:152-169. (PMID: 27687912)
Nucleic Acids Res. 2014;42(16):10448-59. (PMID: 25143535)
Biochem Biophys Res Commun. 2018 Apr 15;498(4):817-823. (PMID: 29530526)
J Lipid Res. 2005 May;46(5):1047-52. (PMID: 15741649)
EMBO Rep. 2001 Jan;2(1):42-8. (PMID: 11252722)
Front Endocrinol (Lausanne). 2013 Jan 25;4:1. (PMID: 23355833)
J Biol Chem. 2000 Jun 2;275(22):16543-9. (PMID: 10748047)
Int J Biochem Cell Biol. 2017 Oct;91(Pt B):145-155. (PMID: 28673892)
Nat Commun. 2017 Jul 31;8(1):162. (PMID: 28757615)
Biochim Biophys Acta. 2010 Aug;1801(8):917-23. (PMID: 20211758)
Nat Neurosci. 2003 Apr;6(4):345-51. (PMID: 12658281)
Genes Dev. 2017 Jun 15;31(12):1202-1211. (PMID: 28747429)
Am J Hum Genet. 2018 May 3;102(5):744-759. (PMID: 29656859)
Neurosci Lett. 2001 Nov 13;314(1-2):45-8. (PMID: 11698143)
ACS Chem Biol. 2010 Nov 19;5(11):1029-34. (PMID: 20735016)
Front Aging Neurosci. 2015 Jun 19;7:119. (PMID: 26150787)
Sci Rep. 2017 Oct 24;7(1):13898. (PMID: 29066835)
PLoS One. 2015 Sep 18;10(9):e0137955. (PMID: 26383638)
Cell. 1998 May 29;93(5):693-704. (PMID: 9630215)
J Intern Med. 2011 Oct;270(4):377-87. (PMID: 21486371)
J Biol Chem. 2011 Jul 15;286(28):24666-73. (PMID: 21613228)
Mol Aspects Med. 2009 Jun;30(3):171-9. (PMID: 19248803)
J Lipid Res. 2004 Aug;45(8):1375-97. (PMID: 15254070)
J Biol Chem. 1990 May 15;265(14):8190-7. (PMID: 2335522)
Steroids. 2015 Jul;99(Pt B):189-93. (PMID: 25668615)
PLoS Genet. 2008 Jul 25;4(7):e1000133. (PMID: 18654640)
Cell Rep. 2017 Jul 5;20(1):124-135. (PMID: 28683306)
Neurotherapeutics. 2008 Jul;5(3):481-9. (PMID: 18625459)
J Lipid Res. 2000 Feb;41(2):195-8. (PMID: 10681402)
Chem Phys Lipids. 2011 Sep;164(6):457-68. (PMID: 21703250)
J Neurochem. 2006 Mar;96(6):1778-89. (PMID: 16539693)
ACS Chem Neurosci. 2016 Feb 17;7(2):143-8. (PMID: 26625251)
J Biol Chem. 2013 Dec 27;288(52):37154-65. (PMID: 24226095)
J Lipid Res. 2004 Jan;45(1):186-93. (PMID: 14523054)
Mol Metab. 2016 Jul 25;5(10):997-1005. (PMID: 27689012)
J Biol Chem. 2001 Oct 5;276(40):37004-10. (PMID: 11463788)
Grant Information:
GARP 2019-103 Fukuyama University
Contributed Indexing:
Keywords: 24S-hydroxycholesterol; Alzheimer’s disease; CYP39A1; cholesterol metabolism; intronic response element; oxysterols; retinoic acid receptor-related orphan receptor α
Substance Nomenclature:
0 (Hydroxycholesterols)
0 (Nuclear Receptor Subfamily 1, Group F, Member 1)
0 (RORA protein, human)
47IMW63S3F (24-hydroxycholesterol)
EC 1.14.- (Steroid Hydroxylases)
EC 1.14.14.26 (CYP39A1 protein, human)
Entry Date(s):
Date Created: 20200513 Date Completed: 20210210 Latest Revision: 20210210
Update Code:
20240105
PubMed Central ID:
PMC7246805
DOI:
10.3390/ijms21093309
PMID:
32392803
Czasopismo naukowe
Oxysterols, important regulators of cholesterol homeostasis in the brain, are affected by neurodegenerative diseases. Early-onset Alzheimer's disease is associated with higher levels of circulating brain-derived 24S-hydroxycholesterol (24S-OHC). Conversion of cholesterol to 24S-OHC is mediated by cholesterol 24S-hydroxylase in the brain, which is the major pathway for oxysterol elimination, followed by oxidation through hepatic first-pass metabolism by CYP39A1. Abnormal CYP39A1 expression results in accumulation of 24S-OHC, influencing neurodegenerative disease-related deterioration; thus, it is important to understand the normal elimination of 24S-OHC and the system regulating CYP39A1, a selective hepatic metabolic enzyme of 24S-OHC. We examined the role of transcriptional regulation by retinoic acid receptor-related orphan receptor α (RORα), a nuclear receptor that responds to oxysterol ligands. In humans, the promoter and first intronic regions of CYP39A1 contain two putative RORα response elements (ROREs). RORα binding and responses of these ROREs were assessed using electrophoretic mobility shift, chromatin immunoprecipitation, and luciferase reporter assays. CYP39A1 was upregulated by RORα overexpression in HEK293 cells, while RORα knockdown by siRNA significantly downregulated CYP39A1 expression in human hepatoma cells. Additionally, CYP39A1 was induced by RORα agonist treatment, suggesting that CYP39A1 expression is activated by RORα nuclear receptors. This may provide a way to increase CYP39A1 activity using RORα agonists, and help halt 24S-OHC accumulation in neurodegenerative illnesses.
Competing Interests: The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies